Shares of Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 45.26 and traded as low as GBX 41. Faron Pharmaceuticals Oy shares last traded at GBX 43.99, with a volume of 38,071 shares.
Faron Pharmaceuticals Oy Stock Up 5.9%
The company has a market cap of £89.78 million, a PE ratio of -2.04 and a beta of 1.11. The company’s 50 day moving average is GBX 45 and its 200 day moving average is GBX 118.61. The company has a current ratio of 0.84, a quick ratio of 1.09 and a debt-to-equity ratio of -133.35.
About Faron Pharmaceuticals Oy
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Further Reading
- Five stocks we like better than Faron Pharmaceuticals Oy
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
